NuCana plc ADR Dossier - Source-backed chat

NuCana plc ADR

NCNANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.79

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.17Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.9M

Enterprise Value −$19.4M

Shares Outstanding 4.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NuCana plc is a clinical-stage biopharmaceutical company leveraging its proprietary ProTide technology to transform widely prescribed nucleoside analogs into more effective and safer cancer therapies. The company's lead candidate, NUC-7738, is advancing through a Phase 2 expansion study (NuTide:701) in combination with pembrolizumab for patients with PD-1 inhibitor-resistant metastatic melanoma, with final data expected in late 2026. Following FDA IND clearance in April 2026, NuCana is well-positioned to initiate clinical trials in the US and seek a registrational pathway. Crucially, the company's cash runway has been extended into 2029, significantly de-risking its near-to-mid-term development timeline and reducing immediate dilution concerns.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.7715%

Final Phase 2 data for NUC-7738 fails to show meaningful clinical efficacy or reveals unexpected safety concerns, halting the melanoma program. Regulatory feedback from the FDA is unfavorable, forcing the company to rely solely on early-stage NUC-3373 combinations, which severely depresses the stock price and shortens the effective cash runway due to strategic pivots.

Base CaseCentral scenario

$25.5060%

NuCana successfully completes enrollment and reports positive, incremental Phase 2 data for NUC-7738 in late 2026, confirming its therapeutic potential. The company obtains constructive regulatory guidance from the FDA to design a registrational trial, while its cash runway remains solid into 2029, supporting steady pipeline progression.

Bull CaseUpside scenario

$26.2525%

The Phase 2 NuTide:701 study yields highly positive final data in late 2026, demonstrating superior efficacy and safety in PD-1 resistant melanoma. The FDA provides a clear, accelerated registrational pathway for NUC-7738, and the company secures a lucrative global co-development partnership with a major pharmaceutical firm, driving substantial upward re-rating.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary ProTide technology platform designed to bypass key cancer resistance mechanisms.
NUC-7738 has demonstrated encouraging clinical activity and a favorable safety profile in heavily pre-treated PD-1 resistant melanoma patients.
FDA IND clearance received in April 2026, enabling clinical expansion into the United States.
Strong balance sheet with £21.5 million in cash as of March 31, 2026, providing a runway into 2029.
Strengthened executive leadership with the appointments of Theresa Bruce as COO and Ian Webster as CFO in early 2026.

Key Investment Risks

High clinical development risk inherent to clinical-stage oncology assets.
Potential regulatory delays or failure to secure an accelerated registrational pathway from the FDA.
Historical clinical setbacks, such as the discontinuation of the Phase 2 colorectal cancer study for NUC-3373 in late 2024.
Extreme stock price volatility and historical long-term downward trend.

Thesis Invalidation Triggers

Failure of NUC-7738 to meet efficacy endpoints in the final Phase 2 NuTide:701 data readout in late 2026.
FDA refusal to support a registrational pathway for NUC-7738 in melanoma.
Unexpected severe adverse safety events leading to clinical holds on lead programs.
Significant acceleration in cash burn rate that shortens the projected runway to well before 2029.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.